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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is considered a major challenge 
because of its prevalence, difficulties in diagnosis, complex pathogenesis, and lack 
of approved therapies. It will become the main cause of chronic liver disease in 
adults and children and the leading indication for liver transplantation (LT) in the 
next decades replacing hepatitis C virus (HCV) infection [1]. It is characterized by 
excessive hepatic fat accumulation, associated with insulin resistance (IR), where 
liver pathology shows steatosis in >5% of hepatocytes or a proton density fat frac-
tion >5.6% assessed by proton magnetic resonance spectroscopy (1HMRS) or quan-
titative fat/water selective magnetic resonance imaging (MRI) [2]. It represents a 
group of conditions ranging from simple asymptomatic liver steatosis (nonalcoholic 
fatty liver (NAFL)) (known by imaging or histology) to cirrhosis (nonalcoholic 
steatohepatitis (NASH) or cryptogenic), end stage liver disease (ESLD), and hepa-
tocellular carcinoma (HCC), passing through nonalcoholic steatohepatitis (NASH), 
which is characterized by the presence of apoptosis, ballooning, inflammation, and 
fibrosis with the absence of secondary causes of hepatic fat accumulation such as 
significant alcohol consumption or viral infection [3]. In the majority of patients, 
NAFLD is commonly associated with metabolic comorbidities such as obesity, type 
2 DM (T2DM), and dyslipidemia. So it became common after increased prevalence 
of these comorbidities [4].
Our book discusses some new topics related to NAFLD, where we divided it 
into four sectors: the first sector includes introductory chapter about NAFLD; the 
second sector contains experimental work related to the disease, while the third 
sector discusses diseases related to NAFLD; and finally the fourth sector includes a 
new noninvasive tool to diagnose NAFLD. The book gives hints regarding NAFLD 
prevalence, etiology, pathogenesis, pathology, diagnosis, and treatment.
This introductory chapter discusses the recent updated data on the prevalence, 
natural history, pathophysiology, pathology, diagnosis, and treatment of the 
disease.
2. Natural history and disease progression
NAFLD prevalence in general population ranges between 13.48 and 31.79% dif-
fering according to diagnostic method, age, sex, and ethnicity [5, 6], while NASH 
prevalence in the general population ranges between 1.5 and 6.45% [5]. It is a slowly 
progressive disease [7]. Patients with histological NASH, especially those with some 
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degree of fibrosis, are at higher risk for disease progression and adverse outcomes 
such as decompensated cirrhosis, HCC, LT, or liver-related mortality [5, 8].
3. Pathogenesis
NAFLD is tightly associated with IR not only in the liver but also in muscle and 
adipose tissues and also with metabolic syndrome (MetS), defined as the cluster of 
any three of the following five features associated with IR: impaired fasting glu-
cose (IFG) or T2DM, hypertriglyceridemia, low high-density lipoprotein (HDL), 
increased waist circumference (WC), and high blood pressure. So, the presence of 
MetS in any given patient should lead to an evaluation of the risk of NAFLD and 
vice versa [9].
A high-calorie diet, saturated fats, and a high fructose intake have been associ-
ated with obesity and NAFLD [10]. It is documented that visceral obesity is one of 
NASH predictors; it is associated with insulin resistance, oxidative stress, inflam-
matory cascade, and overflow of portal triglycerides [11, 12]. So, follow-up of the 
disease and its progression is mandatory in obese persons.
T2DM is associated with NAFLD severity, NASH development, advanced 
fibrosis, and HCC [13]. It is also related to IR, obesity, dyslipedemia, and elevated 
liver enzymes [14].
Recently, multiple parallel hits are responsible for NAFLD pathogenesis and 
progression (i.e., impaired mitochondrial adenosine triphosphate (ATP) activity 
[15], depletion of mitochondrial glutathione [16, 17], hypoxia associated with 
impaired blood flow or obesity-related obstructive sleep apnea [18], dysregulated 
adipokine production [19], the effects of a high fructose diet [20], and rapid 
weight loss [21]).
However, hepatic iron is a source of oxidative stress and hepatocyte dysfunction; 
its role in NAFLD and NASH remains controversial [22].
Both animal and human studies support the concept that the hepatocellular 
injury in NAFL persons that lead to NASH is caused by overload of primary meta-
bolic substrates (glucose, fructose, and fatty acids) in the liver, resulting in diver-
sion of fatty acids into pathways that promote cellular injury and dysfunctional 
response to that injury [23, 24].
In human models and in the setting of established IR and a diet high in saturated 
fats, hepatic traffic of excess free fatty acids (FFA) induces hepatocyte injury via 
lipotoxicity, caused by oxidative stress through the generation of lipotoxic metabo-
lites (such as ceramides, diacylglycerols, and lysophosphatidyl choline) and reactive 
oxygen species (ROS) [25]. However, in animal models, the oxidative stress that 
occurs in the setting of obesity-related IR and lipotoxicity is central to hepatocyte 
injury and is critical to the pathogenesis of NASH [26].
It is documented that lipotoxicity leads to hepatic cell injury and death, via 
apoptosis and/or necrosis, and this is an important driver of inflammation, NASH, 
and fibrosis [27, 28]. Oxidative stress is a major driver of hepatocyte senescence 
that represents a cellular stress response and an irreversible cell cycle arrest aimed 
to limit the proliferation of damaged cells and subsequent tumor development. 
Furthermore, senescent cells can mediate NAFLD progression via the active 
secretion of pro-inflammatory factors that affect the microenvironment, and this 
represents the adoption of a “senescence-associated secretory phenotype” (SASP) 
[26]. In NASH, the inflammatory response includes both the innate and adap-
tive immunity; the cascade begins with hepatocyte injury in the setting of IR and 
lipotoxicity and is propagated by cellular apoptosis, culminating with the activation 
of hepatic stellate cells (HSCs) and ensuing fibrosis [26].
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In short, the pathogenesis of NASH goes as follows: Hepatocytes are affected by 
lifestyle factors as a high saturated fatty acid (SFA) diet, obesity, IR, and hepatic 
steatosis; these multiple parallel metabolic hits lead to cellular damage, via a process 
called “lipotoxicity,” involving excessive oxidative stress principally driven by the 
lipotoxic metabolites of SFA. Injured hepatocytes release damage-associated meta-
bolic patterns (DAMPs) that initiate an inflammatory response, predominantly via 
toll-like receptors (TLRs) and activate pro-inflammatory signaling pathways in the 
setting of increased adipokine levels. Furthermore, injured hepatocytes undergo 
necrosis, apoptosis, and senescence that have a great role in disease progression. 
Direct recruitment of Kupffer cells (KC) and other components of the innate 
immune response occurs with activation of the inflammasome and the coordinated 
release of pro-inflammatory and pro-fibrogenic cytokines and ligands (e.g., Hh, 
OPN). Also, KC promotes a pro-inflammatory microenvironment that initiates 
adaptive immune response. HSC are subsequently activated to produce extracellular 
matrix leading to progressive fibrosis, cirrhosis, and its complications (e.g., HCC). 
Engulfment of apoptotic bodies and factors produced by senescent cells (SASP) can 
also influence HSC activity directly [26].
4. Diagnosis
NAFL encompasses (a) steatosis alone; (b) steatosis with lobular or portal 
inflammation, without ballooning; or (c) steatosis with ballooning but without 
inflammation. The diagnosis of NASH requires the joint presence of steatosis, 
ballooning, and lobular inflammation. So, liver biopsy is essential for its diagnosis 
[29]. Biopsy should give comment on steatosis severity (mild, moderate, or severe). 
Specific scoring systems such as NAFLD activity score (NAS) and/or steatosis 
activity fibrosis (SAF) may be appropriate. Moreover, the presence or absence 
of fibrosis should be described (stage 1 is zone 3 (perivenular or perisinusoidal 
fibrosis) or periportal fibrosis, stage 2 is both zone 3 and periportal fibrosis, stage 
3 is bridging fibrosis with nodularity, and stage 4 is cirrhosis) [5]. Because of liver 
biopsy invasive nature, sampling errors, cost, and its related morbidity and mortal-
ity and noninvasive tools to detect NAFL and NASH were thoroughly studied and 
developed. They have the following advantages: (i) identification of the risk of 
NAFLD in people with high metabolic risk in primary care settings, (ii) identifica-
tion of those with worse prognosis (i.e., severe NASH) in secondary and tertiary 
care settings, and (iii) disease progression and therapeutic response monitoring [2]. 
US, computed tomography (CT), and MRI are noninvasive diagnostic methods of 
moderate and severe steatosis, and they can provide additional hepatobiliary infor-
mation; hence, they should be performed as first-line diagnostic tools for steatosis 
[2]. Moreover, MRI, either by spectroscopy (MRS) or by proton density fat fraction 
(PDFF), is a good noninvasive tool for quantifying steatosis [5]; furthermore, the 
best-validated steatosis scores are the fatty liver index (FLI) and the SteatoTest and 
the NAFLD liver fat score; they variably predict metabolic, hepatic, and cardiovas-
cular outcomes [2]. Regarding NASH, clinical, biochemical, and imaging measures 
cannot distinguish it from steatosis. However, cytokeratin-18 fragments (CK-18), 
which are generated during cell death or apoptosis, have modest accuracy for the 
diagnosis of NASH (66% sensitivity, 82% specificity) [5, 30]. Clinical decision 
aids (e.g., NAFLD fibrosis score (NFS), FIB-4 index, aspartate aminotransferase 
[AST] to platelet ratio index [APRI]), serum biomarkers (enhanced liver fibrosis 
[ELF] panel, fibrometer, FibroTest, and Hepascore), or imaging (e.g., vibration 
controlled transient elastography (VCTE; FibroScan), MR elastography [MRE], 
acoustic radiation force impulse imaging, and supersonic shear wave elastography) 
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are acceptable noninvasive procedures for the identification of cases with advanced 
fibrosis or cirrhosis; furthermore, their combination might confer additional diag-
nostic accuracy, and monitor disease progression, saving a number of diagnostic 
liver biopsies [5].
5. Treatment
It is considered that NAFLD treatments are limited; as the pathogenesis of NASH 
(as discussed above) involves the complex interaction of cellular responses to chronic 
injury, furthermore, the development of the disease over many years cannot be easily 
repaired with short-term intervention (most updated studies have involved short-term 
treatment only); moreover, NAFLD is thought to be a heterogeneous disease [26]. The 
management of NAFLD should consist of treating liver disease as well as the associated 
metabolic comorbidities such as obesity, hyperlipidemia, IR, and T2DM [5].
NAFLD can be treated with lifestyle changes (i.e., healthy diet and habitual 
physical activity) as weight loss results in improvement of liver enzymes and 
histology (steatosis, hepatocyte ballooning, and necroinflammtion) and healthy 
diet improves IR; moreover, both aerobic exercise and resistance training reduce 
liver fat with no need for drug therapy if there is no NASH or fibrosis [31, 32]. 
However, successful treatment of NASH should improve outcomes, i.e., decrease 
NASH-related mortality, and reduce progression to cirrhosis or HCC [2]; this can 
be achieved with drug therapy that is indicated for progressive NASH (bridging 
fibrosis and cirrhosis), for early-stage NASH with increased risk of fibrosis progres-
sion (age > 50 years; diabetes, MetS, increased ALT) [33], and for active NASH with 
high necro-inflammatory activity [34].
The oxidative stress from lipotoxicity has a central role in disease progression, 
and therefore, the use of antioxidants and other approaches to limit this oxidative 
stress was considered. In some studies, vitamin E (800 IU/day) as an antioxidant 
improved steatosis, inflammation, and ballooning and induced resolution of NASH 
[35]. It may be used in non-cirrhotic nondiabetic NASH patients, but further stud-
ies are needed before making firm recommendations.
Ursodeoxycholic acid (UDCA) has been investigated in several RCTs as a treat-
ment for NASH at different doses for up to 2 years with some biochemical improve-
ment without any histological effect [36–38]. Recently, a negative correlation was 
shown between the degree of coffee intake as antioxidant and fibrosis stage in 
NASH. However, the role of phlebotomy in management of NASH by decreasing 
hepatic iron overload and its oxidative stress effect is still controversial. On the other 
hand and despite being under study, newer approaches for managing NASH were 
developed (pentoxifylline, infliximab, NK inhibitors, STAT3 blockade, and anti-CD3 
therapy); they aimed at affecting the intercellular mechanisms that have a role in the 
pathogenesis of NASH. Also, the use of specific medical therapies that are effective in 
patients with metabolic comorbidities (e.g., insulin sensitizing agents (pioglitazone), 
statins, angiotensin-converting-enzyme inhibitors, and angiotensin-receptor block-
ers) has also been tried in patients with NASH with promising results [26].
Bariatric surgery decreases liver fat and NASH progression by treating obesity, 
IR, and diabetes; prospective data showed an improvement in histological NASH 
lesions, including fibrosis [39–41].
Lastly, LT is an accepted procedure in NASH patients with ESLD, liver failure, or 
HCC with comparable overall survival to other indications, despite a higher cardio-
vascular mortality [42, 43].
Finally, I think the book will give readers important knowledge regarding 
NAFLD.
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